Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 45, 2015 - Issue 5
350
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Metabolism and disposition of a potent and selective JNK inhibitor [14C]tanzisertib following oral administration to rats, dogs and humans

, , , &
Pages 428-441 | Received 16 Oct 2014, Accepted 19 Nov 2014, Published online: 08 Dec 2014

References

  • Alcorn JF, van der Velden J, Brown AL, et al. (2009). c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis. Am J Respir Cell Mol Biol 40:422–32
  • Bogoyevitch MA, Kobe B. (2006). Uses for JNK: the many and varied substrates of the c-Jun N-terminal kinases. MMBR 70:1061–95
  • Davis RJ. (2000). Signal transduction by the JNK group of MAP kinases. Cell 103:239–52
  • De Borst MH, Prakash J, Melenhorst WB, et al. (2007). Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J Pathol 213:219–28
  • Deponte M. (2013). Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim Biophys Acta 1830:3217–66
  • Hashimoto S, Gon Y, Takeshita I, et al. (2001). Transforming growth factor-beta1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun-NH2-terminal kinase-dependent pathway. Am J Respir Crit Care Med 163:152–7
  • Hirom PC, Millburn P, Smith RL, Williams RT. (1972). Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions. Biochem J 129:1071–7
  • Lim AK, Ma FY, Nikolic-Paterson DJ, et al. (2011). Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats. Am J Nephrol 34:337–46
  • Ma FY, Flanc RS, Tesch GH, et al. (2007). A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis. JASN 18:472–84
  • Molad Y, Amit-Vasina M, Bloch O, et al. (2010). Increased ERK and JNK activities correlate with disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 69:175–80
  • Plantevin Krenitsky V, Nadolny L, Delgado M, et al. (2012). Discovery of CC-930, an orally active anti-fibrotic JNK inhibitor. Bioorg Med Chem Lett 22:1433–8
  • Prakash C, Soliman V. (1997). Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS. Drug Metab Dispos 25:1288–97
  • Reich N, Tomcik M, Zerr P, et al. (2012). Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 71:737–45
  • Stepan AF, Walker DP, Bauman J, et al. (2011). Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345–410
  • Tanaka Y, Deguchi Y, Ishii I, Terai T. (1991). Sex differences in excretion of zenarestat in rat. Xenobiotica 21:1119–25

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.